A new perspective in the field of cardiac safety testing through the comprehensive in vitro proarrhythmia assay paradigm

Journal of Biomolecular Screening

Volumn 21, Issue 1, 2016, Pages 1-11

  Fermini, Bernard ^a   Hancox, Jules C ^b   Abi Gerges, Najah ^c,s   Bridgland Taylor, Matthew ^c   Chaudhary, Khuram W ^d   Colatsky, Thomas ^e   Correll, Krystle ^f   Crumb, William ^g   Damiano, Bruce ^h   Erdemli, Gul ⁱ   Gintant, Gary ^j   Imredy, John ^k   Koerner, John ^e   Kramer, James ^l   Levesque, Paul ^m   Li, Zhihua ^e   Lindqvist, Anders ⁿ   Obejero Paz, Carlos A ^l   Rampe, David ^o   Sawada, Kohei ^p   Strauss, David G ^q   Vandenberg, Jamie I ^r   more..

^a PFIZER INC   (United States)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^f Safety Pharmacology Society   (United States)

^g ZENAS TECHNOLOGIES LLC   (United States)

^h JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

ⁱ NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^j ABBVIE INC   (United States)

^k MERCK RESEARCH LABORATORIES   (United States)

^l ChanTest   (United States)

^m BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

ⁿ Biolin Scientific   (Denmark)

^o SANOFI   (France)

^p EISAI CO LTD   (Japan)

^q CENTER FOR DEVICES AND RADIOLOGICAL HEALTH   (United States)

^r UNIVERSITY OF NEW SOUTH WALES   (Australia)

^s ANABIOS CORPORATION   (United States)

more..

Author keywords

CiPA; Comprehensive In Vitro Proarrhythmic Assay; hERG; ICH E14; ICH S7B; QT interval; Safety

Indexed keywords

ANTIARRHYTHMIC AGENT; ASTEMIZOLE; AZIMILIDE; BEPRIDIL; CHLORPROMAZINE; CISAPRIDE; CLARITHROMYCIN; CLOZAPINE; DILTIAZEM; DOFETILIDE; DOMPERIDONE; DROPERIDOL; IBUTILIDE; LORATADINE; METHADONE; METOPROLOL; MEXILETINE; NITRENDIPINE; ONDANSETRON; PIMOZIDE; POTASSIUM CHANNEL HERG; QUINIDINE; RANOLAZINE; RISPERIDONE; SOTALOL; TAMOXIFEN; TERFENADINE; VANDETANIB; VERAPAMIL;

CARDIOVASCULAR RISK; COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY; COMPUTER MODEL; DRUG SAFETY; EVALUATION STUDY; FLUX ASSAY; HEART ARRHYTHMIA; HEART REPOLARIZATION; HUMAN; MUSCLE STEM CELL; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK ASSESSMENT; SIMULATION; STANDARDIZATION; SUDDEN DEATH; TORSADE DES POINTES; ANIMAL; ARRHYTHMIAS, CARDIAC; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEART; LONG QT SYNDROME; TORSADES DE POINTES;

ANIMALS; ARRHYTHMIAS, CARDIAC; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEART; HUMANS; LONG QT SYNDROME; TORSADES DE POINTES;

EID: 84951154673     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057115594589     Document Type: Review

References (50)

1. Yap Y. G., Camm A. J., Drug Induced QT Prolongation and Torsades de Pointes. Heart 2003, 89, 1363-1372.
2. Trinkley K. E., Page R. L., Lien H., et al. QT Interval Prolongation and the Risk of Torsades de Pointes: Essentials for Clinicians. Curr. Med. Res. Opin. 2013, 29, 1719-1726.
3. Gintant G. A., Preclinical Torsades-de-Pointes Screens: Advantages and Limitations of Surrogate and Direct Approaches in Evaluating Proarrhythmic Risk. Pharmacol. Ther. 2008, 119, 199-209.
4. Gintant G. A., Su Z., Martin R. L., et al. Utility of hERG Assays as Surrogate Markers of Delayed Cardiac Repolarization and QT Safety. Toxicol. Pathol. 2006, 34, 81-90.
5. Hancox J. C., McPate M. J., El Harchi A., et al. The hERG Potassium Channel and hERG Screening for Drug-Induced Torsades de Pointes. Pharmacol. Ther. 2008, 119, 118-132.
6. Zhang S., Zhou Z., Gong Q., et al. Mechanism of Block and Identification of the Verapamil Binding Domain to HERG Potassium Channels. Circ. Res. 1999, 84, 989-998.
7. Redfern W. S., Carlsson L., Davis A. S., et al. Relationships between Preclinical Cardiac Electrophysiology, Clinical QT Interval Prolongation and Torsade de Pointes for a Broad Range of Drugs: Evidence for a Provisional Safety Margin in Drug Development. Cardiovasc. Res. 2003, 58, 32-45.
8. ICH S7B Note for Guidance on the Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals; International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: London, May 25, 2005. Reference CHMP/ICH/423/02.
9. ICH E14 Note for Guidance on the Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Nonantiarrhythmic Drugs. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER): Rockville, MD, May 25, 2005. Reference CHMP/ICH/2/04.
10. Darpo B., Garnett C., Benson C. T., et al. Cardiac Safety Research Consortium: Can the Thorough QT/QTc Study Be Replaced by Early QT Assessment in Routine Clinical Pharmacology Studies? Scientific Update and a Research Proposal for a Path Forward. Am. Heart J. 2014, 168, 262-272.
11. Sager P. T., Gintant G., Turner J. R., et al. Rechanneling the Cardiac Proarrhythmia Safety Paradigm: A Meeting Report from the Cardiac Safety Research Consortium. Am. Heart J. 2014, 167, 292-300.
12. Pollard C. E., Abi G. N., Bridgland-Taylor M. H., et al. An Introduction to QT Interval Prolongation and Non-Clinical Approaches to Assessing and Reducing Risk. Br. J. Pharmacol. 2010, 159, 12-21.
13. Fermini B., Fossa A. A., The Impact of Drug-Induced QT Interval Prolongation on Drug Discovery and Development. Nat. Rev. Drug Discov. 2003, 2, 439-447.
14. Kramer J., Obejero-Paz C. A., Myatt G., et al. MICE Models: Superior to the HERG Model in Predicting Torsade de Pointes. Sci. Rep. 2013, 3, 2100.
15. Mirams G. R., Cui Y., Sher A., et al. Simulation of Multiple Ion Channel Block Provides Improved Early Prediction of Compounds' Clinical Torsadogenic Risk. Cardiovasc. Res. 2011, 91, 53-61.
16. Paakkari I., Cardiotoxicity of New Antihistamines and Cisapride. Toxicol. Lett. 2002, 127, 279-284.
17. Park E., Willard J., Bi D., et al. The Impact of Drug-Related QT Prolongation on FDA Regulatory Decisions. Int. J. Cardiol. 2013, 168, 4975-4976.
18. CIPA Guiding Principles. https://www.ilsiextra.org/hesi/science/cardiac/cipa/Project%20Documents/CIPA%20data%20sharing%20final.pdf. 2015.
19. Friedrichs G. S., Patmore L., Bass A., Non-Clinical Evaluation of Ventricular Repolarization (ICH S7B): Results of an Interim Survey of International Pharmaceutical Companies. J. Pharmacol. Toxicol. Methods 2005, 52, 6-11.
20. Bridgland-Taylor M. H., Hargreaves A. C., Easter A., et al. Optimisation and Validation of a Medium-Throughput Electrophysiology-Based hERG Assay Using IonWorks HT. J. Pharmacol. Toxicol. Methods 2006, 54, 189-199.
21. Danker T., Moller C., Early Identification of hERG Liability in Drug Discovery Programs by Automated Patch Clamp. Front. Pharmacol. 2014, 5, 203.
22. Kr Channels Minimally Comprise hERG 1a and 1b Subunits. J. Biol. Chem. 2004, 279, 44690-44694.
23. Jones D. K., Liu F., Vaidyanathan R., et al. hERG 1b Is Critical for Human Cardiac Repolarization. Proc. Natl. Acad. Sci. U.S.A. 2014, 111, 18073-18077.
24. McDonald T. V., Yu Z., Ming Z., et al. A MinK-HERG Complex Regulates the Cardiac Potassium Current Ikr. Nature 1997, 388, 289-292.
25. Du C., El Harchi A., Zhang H., et al. Modification by KCNE1 Variants of the hERG Potassium Channel Response to Premature Stimulation and to Pharmacological Inhibition. Physiol. Rep. 2013, 1, e00175.
26. Abbott G. W., Sesti F., Splawski I., et al. MiRP1 Forms Ikr Potassium Channels with HERG and Is Associated with Cardiac Arrhythmia. Cell 1999, 97, 175-187.
27. Sesti F., Abbott G. W., Wei J., et al. A Common Polymorphism Associated with Antibiotic-Induced Cardiac Arrhythmia. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 10613-10618.
28. Weerapura M., Nattel S., Chartier D., et al. A Comparison of Currents Carried by HERG with and without the Coexpression of MiRP1, and the Native Rapid Delayed Rectifier Current. Is MiRP1 the Missing Link? J. Physiol. 2002, 540, 15-27.
29. Yang T., Snyders D. J., Roden D. M., Drug Block of Ikr: Model Systems and Relevance to Human Arrhythmias. J. Cardiovasc. Pharmacol. 2001, 38, 737-744.
30. Kirsch G. E., Trepakova E. S., Brimecombe J. C., et al. Variability in the Measurement of hERG Potassium Channel Inhibition: Effects of Temperature and Stimulus Pattern. J. Pharmacol. Toxicol. Methods 2004, 50, 93-101.
31. Yao J. A., Du X., Lu D., et al. Estimation of Potency of HERG Channel Blockers: Impact of Voltage Protocol and Temperature. J. Pharmacol. Toxicol. Methods 2005, 52, 146-153.
32. Milnes J. T., Witchel H. J., Leaney J. L., et al. Investigating Dynamic Protocol-Dependence of hERG Potassium Channel Inhibition at 37 Degrees C: Cisapride versus Dofetilide. J. Pharmacol. Toxicol. Methods 2010, 61, 178-191.
33. Hanson L. A., Bass A. S., Gintant G., et al. ILSI-HESI Cardiovascular Safety Subcommittee Initiative: Evaluation of Three Non-Clinical Models of QT Prolongation. J. Pharmacol. Toxicol. Methods 2006, 54, 116-129.
34. Sanguinetti M. C., Chen J., Fernandez D., et al. Physicochemical Basis for Binding and Voltage-Dependent Block of hERG Channels by Structurally Diverse Drugs. Novartis. Found. Symp. 2005, 266, 159-166.
35. Shah R. R., Hondeghem L. M., Refining Detection of Drug-Induced Proarrhythmia: QT Interval and TRIaD. Heart Rhythm 2005, 2, 758-772.
36. Gintant G., An Evaluation of hERG Current Assay Performance: Translating Preclinical Safety Studies to Clinical QT Prolongation. Pharmacol. Ther. 2011, 129, 109-119.
37. Antzelevitch C., Cellular Basis for the Repolarization Waves of the ECG. Ann. N.Y. Acad. Sci. 2006, 1080, 268-281.
38. Abriel H., Schlapfer J., Keller D. I., et al. Molecular and Clinical Determinants of Drug-Induced Long QT Syndrome: An Iatrogenic Channelopathy. Swiss. Med. Wkly. 2004, 134, 685-694.
39. DI Veroli G. Y., Davies M. R., Zhang H., et al. High-Throughput Screening of Drug-Binding Dynamics to HERG improves Early Drug Safety Assessment. Am. J. Physiol Heart Circ. Physiol. 2013, 304, H104-H117.
40. O'Hara T., Virag L., Varro A., et al. Simulation of the Undiseased Human Cardiac Ventricular Action Potential: Model Formulation and Experimental Validation. PLoS. Comput. Biol. 2011, 7, e1002061.
41. Yang X., Pabon L., Murry C. E., Engineering Adolescence: Maturation of Human Pluripotent Stem Cell-Derived Cardiomyocytes. Circ. Res. 2014, 114, 511-523.
42. Robertson C., Tran D. D., George S. C., Concise Review: Maturation Phases of Human Pluripotent Stem Cell-Derived Cardiomyocytes. Stem Cells 2013, 31, 829-837.
43. Bett G. C., Kaplan A. D., Lis A., et al. Electronic “Expression†of the Inward Rectifier in Cardiocytes Derived from Human-Induced Pluripotent Stem Cells. Heart Rhythm 2013, 10, 1903-1910.
44. Ma J., Guo L., Fiene S. J., et al. High Purity Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes: Electrophysiological Properties of Action Potentials and Ionic Currents. Am. J. Physiol Heart Circ. Physiol. 2011, 301, H2006-H2017.
45. Rao C., Prodromakis T., Kolker L., et al. The Effect of Microgrooved Culture Substrates on Calcium Cycling of Cardiac Myocytes Derived from Human Induced Pluripotent Stem Cells. Biomaterials 2013, 34, 2399-2411.
46. Lee Y. K., Ng K. M., Lai W. H., et al. Calcium Homeostasis in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Stem Cell Rev. 2011, 7, 976-986.
47. Scott C. W., Zhang X., Abi-Gerges N., et al. An Impedance-Based Cellular Assay Using Human iPSC-Derived Cardio-myocytes to Quantify Modulators of Cardiac Contractility. Toxicol. Sci. 2014, 142, 331-338.
48. Qu Y., Gao B., Fang M., et al. Human Embryonic Stem Cell Derived Cardiac Myocytes Detect hERG-Mediated Repolarization Effects, but Not Nav1.5 Induced Depolarization Delay. J. Pharmacol. Toxicol. Methods 2013, 68, 74-81.
49. Jonsson M. K., Vos M. A., Mirams G. R., et al. Application of Human Stem Cell-Derived Cardiomyocytes in Safety Pharmacology Requires Caution beyond hERG. J. Mol. Cell Cardiol. 2012, 52, 998-1008.
50. Kang J., Chen X. L., Ji J., et al. Ca2+ Channel Activators Reveal Differential L-Type Ca2+ Channel Pharmacology between Native and Stem Cell-Derived Cardiomyocytes. J. Pharmacol. Exp. Ther. 2012, 341, 510-517.